Timing of dose reduction matters: interpreting survival outcomes with CDK4/6 inhibitors in advanced breast cancer

Cancer Chemother Pharmacol. 2026 Apr 7;96(1):31. doi: 10.1007/s00280-026-04879-9.
No abstract available

Publication types

  • Letter